EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER + breast cancer

Anneka L Johnson Thomas, Barbara Karakyriakou, Patricia C Muskus, Alyssa M Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A Birmingham, Malone K Friedman, Abigail E Goen, Huijuan Yang, Owen M Wilkins und 5 weitere

Molecular Oncology · 2026-11 · 20 (11) · 2784-2804

DOI: 10.1002/1878-0261.70307 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 17.07.2026. Verfasst von Anneka L Johnson Thomas und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Systems Biology, Dartmouth Geisel School of Medicine, Lebanon, NH, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Chromatin Assembly and Disassembly, Receptors, Estrogen, Estrogens. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIGMS NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer, but its mechanism of action and strategies to increase efficacy remain unclear. Estrogen therapy can induce ER transcriptional hyperactivation and DNA damage; we postulated that such damage could be exacerbated by epigenetic dysregulation via inhibition of histone deacetylases (HDACi). We evaluated the effects of 17b‐estradiol and HDACi in three types of ER + breast cancer models: Cells adapted to growth following long‐term estrogen deprivation; cells engineered to overexpress exogenous ER that confers endocrine resistance; mice bearing endocrine‐resistant patient‐derived xenografts. Assay endpoints included apoptosis, growth, DNA damage, histone post‐translational modification, levels of ER‐regulated transcripts and encoded proteins, cell cycle and replication status, and genome‐wide chromatin accessibility, ER binding, and transcriptional profiles. Entinostat treatment increased histone acetylation and chromatin accessibility. Combination treatment with E2 and entinostat inhibited cell growth and induced apoptosis in ER‐overexpressing models. E2 and entinostat induced DNA damage as single agents and in combination. These agents synergized against tumor models, offering HDACi as a strategy to enhance efficacy of estrogen therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsChromatin Assembly and DisassemblyReceptors, EstrogenEstrogensEstradiolHumansFemaleAnimalsApoptosisMiceHistone Deacetylase InhibitorsCell Line, TumorBenzamidesHistonesPyridinesDNA DamageCell ProliferationGene Expression Regulation, NeoplasticAcetylationXenograft Model Antitumor Assays

Stichwörter der Autor:innen

breast cancerendocrine resistanceestrogen therapy

Substanzen

Receptors, EstrogenEstrogensEstradiolHistone Deacetylase InhibitorsentinostatBenzamidesHistonesPyridines

Autor:innen und Institutionen

  • Department of Molecular and Systems Biology, Dartmouth Geisel School of Medicine, Lebanon, NH, USA.
  • Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Department of Epidemiology, Geisel School of Medicine, Dartmouth College, Lebanon, NH, USA.
  • Laboratory of Genome Architecture and Dynamics, The Rockefeller University, New York, NY, USA.
  • Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
  • Dartmouth Cancer Center, Dartmouth Geisel School of Medicine, Hanover, NH, USA.

ORCID-Profile: Todd W Miller

Förderung

  • NIH HHS
  • NIGMS NIH HHS
  • NCI NIH HHS
  • National Institutes of Health

Zitieren

APA

Johnson Thomas, A. L., Karakyriakou, B., Muskus, P. C., Roberts, A. M., Rendleman, J., Warren, A., Lu, H., Birmingham, K. A., Friedman, M. K., Goen, A. E., Yang, H., Wilkins, O. M., Kolling, F. W., Demidenko, E., Jorns, J. M., Christensen, B. C., & Miller, T. W. (2026). Pharmacological chromatin remodeling enhances response to estrogen therapy in ER + breast cancer. Molecular Oncology, 20(11), 2784-2804. https://doi.org/10.1002/1878-0261.70307

Vancouver

Johnson Thomas AL, Karakyriakou B, Muskus PC, Roberts AM, Rendleman J, Warren A, et al. Pharmacological chromatin remodeling enhances response to estrogen therapy in ER + breast cancer. Molecular Oncology. 2026;20(11):2784-2804. doi:10.1002/1878-0261.70307

BibTeX
@article{JohnsonThomas2026,
  author = {Johnson Thomas, Anneka L and Karakyriakou, Barbara and Muskus, Patricia C and Roberts, Alyssa M and Rendleman, Justin and Warren, Alexa and Lu, Hanxu and Birmingham, Kimberly A and Friedman, Malone K and Goen, Abigail E and Yang, Huijuan and Wilkins, Owen M and Kolling, Fred W and Demidenko, Eugene and Jorns, Julie M and Christensen, Brock C and Miller, Todd W},
  title = {Pharmacological chromatin remodeling enhances response to estrogen therapy in ER + breast cancer},
  journal = {Molecular Oncology},
  year = {2026},
  volume = {20},
  number = {11},
  pages = {2784--2804},
  doi = {10.1002/1878-0261.70307}
}
Kostenlos starten →